Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently weighed in on RVNC. Piper Sandler cut Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Stifel Nicolaus cut their price target on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 9th. Barclays reaffirmed an “equal weight” rating and issued a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Finally, HC Wainwright downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Ten equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $10.50.

Revance Therapeutics Stock Performance

Shares of RVNC stock opened at $5.19 on Tuesday. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $11.18. The stock has a market cap of $544.02 million, a PE ratio of -1.43 and a beta of 1.00. The stock has a fifty day moving average price of $5.55 and a 200 day moving average price of $4.25.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.12. The company had revenue of $65.39 million during the quarter, compared to analyst estimates of $66.30 million. During the same period last year, the firm earned ($0.80) earnings per share. The business’s revenue was up 20.2% compared to the same quarter last year. As a group, equities research analysts predict that Revance Therapeutics will post -1.53 earnings per share for the current year.

Institutional Investors Weigh In On Revance Therapeutics

A number of institutional investors have recently added to or reduced their stakes in RVNC. Capital World Investors grew its position in Revance Therapeutics by 16.8% during the first quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company’s stock valued at $68,612,000 after acquiring an additional 2,006,459 shares during the period. Stonepine Capital Management LLC grew its position in Revance Therapeutics by 41.7% during the second quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $7,196,000 after acquiring an additional 823,658 shares during the period. CIBC Asset Management Inc grew its position in Revance Therapeutics by 251.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,147,294 shares of the biopharmaceutical company’s stock valued at $10,085,000 after acquiring an additional 820,587 shares during the period. Opaleye Management Inc. purchased a new stake in Revance Therapeutics during the first quarter valued at about $3,862,000. Finally, Federated Hermes Inc. grew its position in Revance Therapeutics by 43.0% during the second quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock valued at $5,750,000 after acquiring an additional 672,803 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.